In the current study, we report strikingly lower rates of grade ≥ 3 adverse events in BRAF/MEK-treated patients compared to the COMBI-AD trial (11.5% versus 41% in the COMBI-AD trial) [1]. This evidence concerns the gene BRAF and Alzheimer disease.